Gamida Cell Ltd. (NASDAQ:GMDA) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET

Company Participants

Heather DiVecchia - Director of IR & Corporate Communications

Julian Adams - CEO

Ronit Simantov - CMO & Chief Scientific Officer

Michele Korfin - COO & Chief Commercial Officer

Shai Lankry - CFO

Conference Call Participants

Edward Tenthoff - Piper Sandler

Jonathan Miller - Evercore

Gilbert Blum - Needham

Mark Breidenbach - Oppenheimer

Operator

Ladies and gentlemen and I will be your Operator for today’s call. Please be advised that this call is being recorded at Gamida Cell’s request.

Now, I would like to introduce your host for today’s conference, Heather DiVecchia, Gamida Cell’s Director of Investor Relations and Corporate Communications. Please go ahead.

Heather DiVecchia

Thank you, [Lydia] and good morning, everyone. Welcome to today’s call during which we will provide an update on the Company and review our financial results for the second quarter of 2022. Earlier this morning, we issued a press release summarizing our financial results and progress across the Company, which is available on our website at www.gamidacell.com.

Here with me on the call today are, Julian Adams, Chief Executive Officer; Ronit Simantov, our Chief Medical Officer and Chief Scientific Officer; Michele Korfin, our Chief Operating Officer and Chief Commercial Officer and Shai Lankry, our Chief Financial Officer.

During this call, we may make Forward-Looking Statements about our future expectations and plans including in respect to the timing of initiation and progress of, and data reported from the pre-clinical and clinical trials of our product candidates, regulatory filings, including the review of the BLA for Omidubicel by the FDA, commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidate, including GDA-201 and Omidubicel, and our expectations regarding our projected cash, cash equivalent, and investment to be used for operating activities.

Our actual results may differ materially from what we project today due to a number of important factors, including the impacts of COVID-19 pandemic on our operations, the scope, progress and expansion of our clinical trials and impact to the cost thereof, clinical, scientific, regulatory and technical developments, those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates, as well as those considerations described in the Risk Factors section of our most recent quarterly report on Form 10-Q and other filings that we make with the SEC from time-to-time.